Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 25;16(1):30.
doi: 10.1186/s41479-024-00149-5.

Mortality reduction with 23-valent pneumococcal polysaccharide vaccine: a systematic review and meta-analysis

Muhammed Shabil #  1   2 , Shilpa Gaidhane #  3 , Suhas Ballal  4 , Sanjay Kumar  5 , Mahakshit Bhat  6 , Shilpa Sharma  7 , M Ravi Kumar  8 , Sarvesh Rustagi  9 , Mahalaqua Nazli Khatib  10 , Nishant Rai  11   12 , Sanjit Sah  13   14 , Edward Mawejje  15 , Ganesh Bushi  16 , Kiran Bhopte  17 , Rachna Kathuria  18 , Ambanna Yappalparvi  19
Affiliations
Review

Mortality reduction with 23-valent pneumococcal polysaccharide vaccine: a systematic review and meta-analysis

Muhammed Shabil et al. Pneumonia (Nathan). .

Abstract

Background: Pneumococcal disease, caused by Streptococcus pneumoniae, imposes a significant global health burden, particularly affecting vulnerable groups such as the elderly and immunocompromised. The 23-valent pneumococcal polysaccharide vaccine (PPV23) is designed to protect against 23 serotypes of Streptococcus pneumoniae. However, there is ongoing debate about its effectiveness in reducing all-cause mortality. This systematic review and meta-analysis aimed to evaluate the efficacy of PPV23 in reducing all-cause and pneumonia-related mortality among adults.

Methods: A systematic search was conducted across PubMed, Embase, and Web of Science, focusing on studies that evaluated the mortality outcomes of adults vaccinated with PPV23 compared to non-vaccinated adults. Both randomized controlled trials (RCTs) and observational studies were included, while case reports, case series, and non-human studies were excluded. Data extraction and quality assessment were facilitated by Nested Knowledge software, using the Newcastle-Ottawa Scale for observational studies and the Cochrane Risk of Bias tool for RCTs.

Results: The search yielded 826 records, with 19 studies meeting the inclusion criteria. The pooled analysis of four RCTs showed no significant reduction in all-cause mortality (RR = 1.030; 95% CI: 0.945, 1.122). However, analysis of pneumonia-related mortality across various studies indicated a significant reduction (HR = 0.504; 95% CI: 0.316, 0.693). Moderate to high heterogeneity was noted in mortality studies, and a potential publication bias was identified.

Conclusion: The findings suggest that while PPV23 may not significantly reduce all-cause mortality, it is effective in reducing pneumonia-related mortality among adults, particularly in those at higher risk. These results support the continued use of PPV23 in targeted adult populations, emphasizing the need for more primary studies to explore its effectiveness across diverse groups.

Keywords: Meta-analysis; Mortality; PPV23; Pneumonia; Vaccination.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval: Not required. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
PRISMA flow diagram depicting the article selection and screening process
Fig. 2
Fig. 2
Forest plot depicting risk of all-cause mortality between vaccinated and unvaccinated Individuals from RCTs
Fig. 3
Fig. 3
Forest plot depicting pooled Hazard ratios for all-cause mortality with vaccination
Fig. 4
Fig. 4
Forest plot depicting pooled Hazard ratios for pneumonia-related mortality with vaccination
Fig. 5
Fig. 5
Forest plot depicting pooled Hazard ratios for pneumonia-related mortality with vaccination
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Wahl B, O’Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15. Lancet Global Health. 2018;6(7):e744–57. - PMC - PubMed
    1. Dhoubhadel BG, Morimoto K. Prevention of pneumococcal diseases: the challenge remains. Lancet Global Health. 2022;10(10):e1375–6. - PubMed
    1. Kumar P, Neyazi A, Rillera Marzo R, Augusto Guimaraes C, Barboza J, Abu Serhan J. H, Mycoplasma pneumoniae returns: understanding its spread and growing impact. Evid. 2024;2(1).
    1. Savoy M, Pneumococcal Vaccine MSD, Manual Professional, Edition. MSD Manual; 2024 [updated 2024/04. https://www.msdmanuals.com/en-in/professional/infectious-diseases/immuni...
    1. Lawrence H, Pick H, Baskaran V, Daniel P, Rodrigo C, Ashton D, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: a case-control test-negative design study. PLoS Med. 2020;17(10):e1003326. - PMC - PubMed

LinkOut - more resources